Philip Sager, MD

SENIOR CLINICAL ADVISOR

Dr. Philip Sager is a cardiac electrophysiologist with an extensive career spanning academia, drug development, and regulatory policy. He was a tenured faculty member at the UCLA School of Medicine and currently serves as an Adjunct Professor of Medicine at the Stanford University School of Medicine.

Dr. Sager has held senior leadership roles in the pharmaceutical industry, including Vice President of CV/Metabolic Development at Gilead Sciences and Executive Director at AstraZeneca. In these roles, he led the development of several major drugs, including Zetia, Vytorin, Crestor, Letairis, and Brilinta, and contributed to multiple NDAs and sNDAs. He also served on the Board of Directors of Anthera, Inc., a public biotechnology company, and is a co-founder of Thryv Therapeutics.

Dr. Sager is a past chair of the FDA Cardiovascular and Renal Drugs Advisory Committee and a Founding Member and Executive Committee member of the FDA-Sponsored Cardiac Safety Research Consortium. He has played a significant international leadership role in cardiovascular safety issues in drug development and public health policy and served as the ICH E14 (the "QT Guidance") PhRMA Expert Working Group Topic Leader.

Dr. Sager holds an MD from Yale University School of Medicine and BSc degrees in Biology and Chemistry from the Massachusetts Institute of Technology. He completed his training in internal medicine, cardiology, and cardiac electrophysiology at Yale School of Medicine. Dr. Sager has authored more than 200 original manuscripts and abstracts.